Spyre Therapeutics slips as $463.5M stock offering adds fresh share supply
Spyre Therapeutics shares fell 3.47% to $70.41 as the market digested a large, recently completed equity raise that expanded share count and increased near-term supply. The company priced 6.5 million shares at $62 and underwriters fully exercised an option for 975,000 more shares, taking gross proceeds to about $463.5 million.
1) What’s moving SYRE today
Spyre Therapeutics (SYRE) traded lower as investors rotated out following a major, recently completed financing that increased the effective tradable share supply. The company sold 6,500,000 shares at $62.00 and the underwriters exercised their 30-day option in full for an additional 975,000 shares, bringing gross proceeds to approximately $463.5 million and lifting shares outstanding as of April 16, 2026. (tradingview.com)
2) Why a deal can pressure a high-momentum biotech
Even when a raise strengthens the balance sheet, the added stock can weigh on near-term price action as new shares are absorbed and traders recalibrate around the offering price. SYRE had surged earlier in April after the company disclosed positive initial 12-week induction topline results from Part A of the Phase 2 SKYLINE trial for SPY001 in ulcerative colitis, creating a setup where a pullback can look like digestion of gains plus financing-related supply. (sec.gov)
3) What to watch next
Near-term focus is on how quickly the market clears the new issuance and whether additional ownership/positioning updates follow, given the post-offering update to shares outstanding referenced in recent major-holder filings. Traders will also be watching upcoming program milestones referenced in the company’s recent SEC materials, since further clinical updates can reassert the narrative that drove the earlier April rally. (stocktitan.net)